>Brookings Oregon News, Sports, & Weather | The Curry Coastal Pilot

News Classifieds Web
web powered by Web Search Powered by Google

News arrow News arrow Business arrow O'HOLLERAN CHOSEN REALTOR OF THE YEAR

O'HOLLERAN CHOSEN REALTOR OF THE YEAR Print E-mail
October 03, 2008 11:00 pm
Mary O'Holleran shows plaque awarded her. (The Pilot/Marjorie Woodfin).
Mary O'Holleran shows plaque awarded her. (The Pilot/Marjorie Woodfin).

By Marjorie Woodfin

Pilot staff writer

The Curry County Board of Realtors is very good at keeping secrets – especially when planning to present the Realtor of Year award.

Mary O'Holleran, Curry County Board of Realtors' Realtor of the Year 2008 said, "I was totally surprised. It's such an honor."

The voting is secret and only the selection committee, members of the board of directors and recipient's spouse know who the winner is until the big announcement is made. The choice is made by the vote of all members.

This year, presenting the award was a bit more difficult because, due to an injured shoulder, O'Holleran was unable to attend the celebration meeting.

She said she couldn't understand why her husband would suggest that she attend the meeting when he knew she was in pain, and she refused to go.

On the morning of the meeting when Dick O'Holleran called to inform board members that his wife would not attend the meeting, they told him that they would make the presentation at the O'Hollerans' home. He warned them that carpet cleaners were there.

Instead of being honored in the presence of her peers, board members, president J.B. White, past president Cy Vandermeer, former recipient Sheryl Watkins and O'Holleran's principal broker Jeannette McVay presented the award plaque at her home with her arm in a sling while the carpet cleaners were busily running their machines.

White said about the award, "I'm tickled to death. Mary was honored for her longevity on the board and especially for her work on the education committee."

Vandermeer said, "It was much deserved. She has worked hard over the years serving others."

 

Business News by Yahoo Finance

  • China shares lead Asia higher, dollar buoyed
    Asian stocks shrugged off a drop in Wall Street and hovered near three-year highs on Monday, with China taking the lead after data showed a robust jump in profits earned by industrial firms in the world's second-largest economy. The two-day Federal Reserve policy review ending on Wednesday was also in focus but expectations were for Chair Janet Yellen to deliver the usual dovish message.
  • JP Morgan questioned on private bank impropriety: WSJ
    As a result of the questioning regarding potential conflicts of interest, the New York-based bank has sharpened its disclosures to clients, the newspaper said, citing sources. The Office of the Comptroller of the Currency, one of JP Morgan's regulators, has been in discussions with the bank regarding the potential conflicts of interest in recent months, according to the report. "Being transparent is part of our normal course of business and it's what drives our client communications," Darin Oduyoye, a spokesman for JP Morgan's asset-management unit, told Reuters on Sunday. If brokers push clients to buy the in-house brand of financial product, rather than provide impartial financial advice, the bank could stand to benefit at the expense of the client.
  • Pfizer's need for deal looms larger with earnings report
    Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline. While many industry watchers expect Pfizer to re-engage with Britain's AstraZeneca in coming months, some say the U.S. drugmaker should consider targets more focused on biotechnology, a strategy that has paid off for Merck & Co and Bristol-Myers Squibb Co. Although Pfizer is conducting trials of promising products - including breast cancer drug palbociclib and vaccines against meningitis and staph aureus - it needs far more drugs to generate meaningful sales growth, said Ori Hershkovitz, analyst with the Tel Aviv-based Sphera Fund, which holds Pfizer shares.     "Pfizer is in a very desperate spot, having seen most of its pipeline disappoint and facing multiple patent expirations," he said.

Follow Curry Coastal Pilot headlines on Follow Curry Coastal Pilot headlines on Twitter

© Copyright 2001 - 2014 Western Communications, Inc. All rights reserved. By Using this site you agree to our Terms of Use